Mitoguazone
Chemical compound
- L01XX16 (WHO)
- (2E,2'E)-2,2'-(1E,2E)-propane-1,2-diylidenedihydrazinecarboximidamide
- 459-86-9 Y
- 5351154
- 4508218 N
- OD5Q0L447W
- D07258 Y
- CHEBI:43996 N
- DTXSID70861943
- Interactive image
- C\C(\C=N\NC(N)=N)=N/NC(N)=N
InChI
- InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+ N
- Key:PKDBCJSWQUOKDO-UHFFFAOYSA-M N
Mitoguazone (also known as methylglyoxal bis(guanylhydrazone) or MGBG) is a drug used in chemotherapy.[1]
References
- ^ Hoffmann H, Gutsche W, Amlacher R, Schulze W, Werner W, Lenk H, Wohlrab W, Haupt E (1989). "[Mitoguazone (methylglyoxal bis(guanylhydrazone))--its status and prospects]". Archiv für Geschwulstforschung (in German). 59 (2): 135–48. PMID 2655552.
- v
- t
- e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e